Valion Bio, Inc. (VBIO) fundamentals score
Tivic Health Systems, Inc. is a late-stage biopharmaceutical company whose lead program is Entolimod. Entolimod is a recombinant TLR5 agonist with an extensive preclinical and clinical data package supporting development as a medical countermeasure (MCM) for Acute Radiation Syndrome (ARS) and it subsyndromes, as well as for adjunct therapy for oncology indications, such as neutropenia.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 3.9 out of 10, Weak long-term fundamentals
- Growth: 4.8/10
- Profitability: 1.1/10
- Financial health: 7.9/10
- Earnings quality: 4.0/10
- Valuation: 1.5/10
Scores are calculated from Valion Bio, Inc.’s SEC filings, using the 12 months through 2025-09. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10